Replies to post #391 on Horizon Therapeutics Public Limited Co (fka HZNP)

[surf1944]

7:30AM Horizon Pharma announces the U.S. Patent and Trademark Office issued an additional notice of allowance with claims covering RAYOS (prednisone) delayed-release tablets (HZNP) 2.44 : Co announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application 13/428,548 entitled "Delayed Release Tablet with Defined Core Geometry" that covers the Company's U.S. approved product RAYOS. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2024.